ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Setting The Standard In Vision Correction: Blue Fin Vision® Shines At ESCRS 2025

Mr Mfazo Hove, Clinical Director at Blue Fin Vision, received the honour of being invited as a featured speaker by ZEISS at the renowned ESCRS 2025 Congress in Copenhagen.

-- Blue Fin Vision is delighted to announce that Clinical Director Mr Mfazo Hove was invited by ZEISS as a main speaker at the recent ESCRS 2025. As the world’s leading cataract and refractive surgery congress, it was an esteemed honour for Mr Hove to speak on the main stage in front of over 15,000 delegates.

Only the best and most prestigious ophthalmic surgeons are invited to speak at this event, so it’s a testament to the brilliance of Blue Fin Vision for its leading surgeon to get the nod. This high-profile session reinforces the clinic’s status as a leader in this industry and supports its Top Recommended status in the Spear’s 2025 Health & Wellness Index. The conference was an opportunity for Mr Hove to reveal some of the clinic’s latest ideas and advancements that are set to take the cataract and refractive surgery world by storm.

Cutting-Edge Technology Reveal

Blue Fin Vision shines at ESCRS 2025 with its revolutionary technology reveal. Mr Hove took this as an opportunity to demonstrate real-world outcomes for the next generation ZEISS intraocular lenses. It was a chance to show how top-tier research translates to immediate patient benefits.

The impact of Mr Hove’s ESCRS 2025 session cannot be overstated. It was more than just a technology showcase; it demonstrated the direct impact for patients across London, Chelmsford, Hatfield and beyond. They’ll gain access to these advancements and can now see just how impressive they are.

Benchmark-Setting Leadership

By presenting at ESCRS, Blue Fin Vision cements its role in defining new standards for vision correction, driving transparency, innovation and patient-centred excellence. It was the 43rd edition of this conference, and receiving an invite as one of the featured speakers is a goal for many surgeons in this industry.

Blue Fin Vision and Mr Hove are delighted to receive such recognition and hope that the added acclaim that comes with this will help even more patients get the help they need. The clinic also looks forward to bringing forth its newest technology in the coming months and years.

About Blue Fin Vision

Blue Fin Vision is a UK-based expert eye care and vision correction clinic offering top-class surgery to numerous patients. It deals with general ophthalmology, as well as specialising in laser eye surgery, cataract surgery, lens replacement surgery and more. The clinic is headlined by Mr Mfazo Hove, who is the lead consultant and surgeon. With over 20 years of experience, Mr Hove brings a wealth of knowledge to Blue Fin Vision and is recommended in the Spear’s 2025 UK Health & Wellness Index.

For more information, visit the website here: https://bluefinvision.com/.

Contact Info:
Name: Bukie
Email: Send Email
Organization: Blue Fin Vision
Phone: 07704225640
Website: https://bluefinvision.com/

Release ID: 89170235

In case of encountering any inaccuracies, problems, or queries arising from the content shared in this press release that necessitate action, or if you require assistance with a press release takedown, we urge you to notify us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be readily available to promptly address your concerns within 8 hours, resolving any identified issues diligently or guiding you through the necessary steps for removal. The provision of accurate and dependable information is our primary focus.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.